Evidence map›Paper›PMID 31852427›Full record

ArticleBMC bioinformatics2019

Evaluation of knowledge graph embedding approaches for drug-drug interaction prediction in realistic settings.

Remzi Celebi, Huseyin Uyar, Erkan Yasar, Ozgur Gumus, Oguz Dikenelli, Michel Dumontier

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Remzi CelebiInstitute of Data Science, Maastricht University, Maastricht, 6200, Netherlands. remzi.celebi@maastrichtuniversity.nl.ORCID http://orcid.org/0000-0001-7769-4272
Huseyin UyarComputer Engineering Department, Ege University, Izmir, 35100, Turkey.
Erkan YasarComputer Engineering Department, Ege University, Izmir, 35100, Turkey.
Ozgur GumusComputer Engineering Department, Ege University, Izmir, 35100, Turkey.
Oguz DikenelliComputer Engineering Department, Ege University, Izmir, 35100, Turkey.
Michel DumontierInstitute of Data Science, Maastricht University, Maastricht, 6200, Netherlands.
Ege University · TRMaastricht University · NL

Funding

Ege Üniversitesi 16-MUH-095 BAPGlobal Collaborative Research, King Abdullah University of Science and Technology URF/1/3454-01-01
6 · The paper itself

Abstract

backgroundCurrent approaches to identifying drug-drug interactions (DDIs), include safety studies during drug development and post-marketing surveillance after approval, offer important opportunities to identify potential safety issues, but are unable to provide complete set of all possible DDIs. Thus, the drug discovery researchers and healthcare professionals might not be fully aware of potentially dangerous DDIs. Predicting potential drug-drug interaction helps reduce unanticipated drug interactions and drug development costs and optimizes the drug design process. Methods for prediction of DDIs have the tendency to report high accuracy but still have little impact on translational research due to systematic biases induced by networked/paired data. In this work, we aimed to present realistic evaluation settings to predict DDIs using knowledge graph embeddings. We propose a simple disjoint cross-validation scheme to evaluate drug-drug interaction predictions for the scenarios where the drugs have no known DDIs.

resultsWe designed different evaluation settings to accurately assess the performance for predicting DDIs. The settings for disjoint cross-validation produced lower performance scores, as expected, but still were good at predicting the drug interactions. We have applied Logistic Regression, Naive Bayes and Random Forest on DrugBank knowledge graph with the 10-fold traditional cross validation using RDF2Vec, TransE and TransD. RDF2Vec with Skip-Gram generally surpasses other embedding methods. We also tested RDF2Vec on various drug knowledge graphs such as DrugBank, PharmGKB and KEGG to predict unknown drug-drug interactions. The performance was not enhanced significantly when an integrated knowledge graph including these three datasets was used.

conclusionWe showed that the knowledge embeddings are powerful predictors and comparable to current state-of-the-art methods for inferring new DDIs. We addressed the evaluation biases by introducing drug-wise and pairwise disjoint test classes. Although the performance scores for drug-wise and pairwise disjoint seem to be low, the results can be considered to be realistic in predicting the interactions for drugs with limited interaction information.

Indexed as

Drug InteractionsBayes TheoremKnowledgeLogistic ModelsPattern Recognition, AutomatedDisjoint cross-validationDrug-drug interactionPaired dataRealistic evaluation

Identifiers

PMID31852427
PMCPMC6921491
OpenAlexW2995738274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.